Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Downregulation of SERINC5 expression in buffy coats of HIV-1-infected patients with detectable or undetectable viral load.
Hernández-López EG, González-Enríquez GV, Torres-Mendoza BM, Cárdenas-Bedoya J, Escoto-Delgadillo M, Vázquez-Valls E, Pérez-Ríos AM, Carbajal-Uribe DA, Rincón-Sánchez AR. Hernández-López EG, et al. Among authors: perez rios am. Mol Biol Rep. 2021 May;48(5):4247-4252. doi: 10.1007/s11033-021-06438-2. Epub 2021 Jun 7. Mol Biol Rep. 2021. PMID: 34097204
MicroRNA-296-5p is differentially expressed in individuals with and without HIV-1 infection.
Cárdenas-Bedoya J, Marquez-Pedroza J, Morán-Moguel MC, Escoto-Delgadillo M, Vázquez-Valls E, González-Enríquez GV, Pérez-Ríos AM, Torres-Mendoza BM. Cárdenas-Bedoya J, et al. Among authors: perez rios am. Genet Mol Biol. 2020 Jun 22;43(3):e20200017. doi: 10.1590/1678-4685-GMB-2020-0017. eCollection 2020. Genet Mol Biol. 2020. PMID: 32584920 Free PMC article.
Genomic instability in people living with HIV.
Gutiérrez-Sevilla JE, Cárdenas-Bedoya J, Escoto-Delgadillo M, Zúñiga-González GM, Pérez-Ríos AM, Gómez-Meda BC, González-Enríquez GV, Figarola-Centurión I, Chavarría-Avila E, Torres-Mendoza BM. Gutiérrez-Sevilla JE, et al. Among authors: perez rios am. Mutat Res Genet Toxicol Environ Mutagen. 2021 May;865:503336. doi: 10.1016/j.mrgentox.2021.503336. Epub 2021 Feb 18. Mutat Res Genet Toxicol Environ Mutagen. 2021. PMID: 33865542
HEPLA: A multicenter study on demographic and disease characteristics of patients with hepatitis C in Latin America.
Viola L, Marciano S, Colombato L, Coelho H, Cheinquer H, Bugarin G, Tatsch F, Carvalho-Filho RJ, Roblero JP, Varon A, Holguin J, Torres-Ibarra MR, Pérez-Ríos AM. Viola L, et al. Among authors: perez rios am. Ann Hepatol. 2020 Mar-Apr;19(2):161-165. doi: 10.1016/j.aohep.2019.09.006. Epub 2019 Oct 24. Ann Hepatol. 2020. PMID: 31718995 Free article.
[Guideline for interpretation and report of the antibody to hepatitis C virus. Grupo de Desarrollo de la Guía ].
Contreras AM, Ochoa-Jiménez RJ, Kershenobich D, Granados-García V, Conde-González CJ, Celis A, Pérez-Gómez HR, Ruelas-Hernández S, Romero-Flores P, Alcántar-Luna E, Sierra-García de Quevedo J, Ancona-Pisté O; Grupo de Desarrollo de la Guía. Contreras AM, et al. Rev Invest Clin. 2012 Nov-Dec;64(6 Pt 2):641-78. Rev Invest Clin. 2012. PMID: 23593783 Spanish.
Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial.
de la Rocha C, Cid-López MA, Venegas-López BI, Gómez-Méndez SC, Sánchez-Ortiz A, Pérez-Ríos AM, Llamas-Velázquez RA, Meza-Acuña AI, Vargas-Íñiguez B, Rosales-Galván D, Tavares-Váldez A, Luna-Gudiño N, Hernández-Puente CV, Milenkovic J, Iglesias-Palomares C, Méndez-Del Villar M, Gutiérrez-Dieck GA, Valderrábano-Roldán CG, Mercado-Cerda J, Robles-Bojórquez JG, Mercado-Sesma AR. de la Rocha C, et al. Among authors: perez rios am. BMC Infect Dis. 2022 Dec 8;22(1):917. doi: 10.1186/s12879-022-07890-6. BMC Infect Dis. 2022. PMID: 36482326 Free PMC article. Clinical Trial.
The Mexican consensus on the treatment of hepatitis C.
Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-Almaguer OD, Castillo-Barradas M, Castro-Narro G, Chávez-Tapia N, Chirino-Sprung RA, Cisneros-Garza L, Dehesa-Violante M, Flores-Calderón J, Flores-Gaxiola A, García-Juárez I, González-Huezo MS, González-Moreno EI, Higuera-de la Tijera F, Kershenobich-Stalnikowitz D, López-Méndez E, Malé-Velázquez R, Marín-López E, Mata-Marín JA, Méndez-Sánchez N, Monreal-Robles R, Moreno-Alcántar R, Muñoz-Espinosa L, Navarro-Alvarez S, Pavia-Ruz N, Pérez-Ríos AM, Poo-Ramírez JL, Rizo-Robles MT, Sánchez-Ávila JF, Sandoval-Salas R, Torre A, Torres-Ibarra R, Trejo-Estrada R, Velarde-Ruiz Velasco JA, Wolpert-Barraza E, Bosques-Padilla F. Aiza-Haddad I, et al. Among authors: perez rios am. Rev Gastroenterol Mex (Engl Ed). 2018 Jul-Sep;83(3):275-324. doi: 10.1016/j.rgmx.2017.11.001. Epub 2018 May 24. Rev Gastroenterol Mex (Engl Ed). 2018. PMID: 29803325 Free article. English, Spanish.
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team. Cahn P, et al. Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Lancet. 2019. PMID: 30420123 Clinical Trial.
13 results